| Zacks Company Profile for Pacira BioSciences, Inc. (PCRX : NSDQ) |
|
|
| |
| • Company Description |
| Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug delivery technology. Pacira changed its name to Pacira BioSciences following the acquisition of MyoScience. Exparel, the company's flagship product, is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. The company signed a licensing agreement with Aratana for the development and commercialization of Exparel for animal health indications.
Number of Employees: 790 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $23.69 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 448,896 shares |
| Shares Outstanding: 46.29 (millions) |
| Market Capitalization: $1,096.63 (millions) |
| Beta: 0.48 |
| 52 Week High: $27.64 |
| 52 Week Low: $11.16 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-3.11% |
-6.74% |
| 12 Week |
-3.89% |
-19.16% |
| Year To Date |
25.74% |
17.76% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
2000 SIERRA POINT PARKWAY 9TH FLOOR
-
BRISBANE,CA 94005
USA |
ph: 650-242-8052
fax: 302-655-5049 |
susan.mesco@pacira.com |
http://www.pacira.com |
|
|
| |
| • General Corporate Information |
Officers
Frank D. Lee - Chief Executive Officer and Director
Shawn M. Cross - Chief Financial Officer
Lauren Riker - Senior Vice President; Finance
Marcelo Bigal - Director
Mark Kronenfeld - Director
|
|
Peer Information
Pacira BioSciences, Inc. (CORR.)
Pacira BioSciences, Inc. (RSPI)
Pacira BioSciences, Inc. (CGXP)
Pacira BioSciences, Inc. (BGEN)
Pacira BioSciences, Inc. (GTBP)
Pacira BioSciences, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 695127100
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/29/25
|
|
Share - Related Items
Shares Outstanding: 46.29
Most Recent Split Date: (:1)
Beta: 0.48
Market Capitalization: $1,096.63 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.46 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $2.06 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/29/25 |
|
|
|
| |
